Know all the precautions for using vanzacato/tizakattor/deuterated ivacaftor composite tablets

Vanzacaftor/tezacaftor/deuterated ivacaftor composite tablet (vanzacaftor, tezacaftor and deutivacaftor) is a new triple therapy for the treatment of cystic fibrosis. Special attention needs to be paid to its potential safety issues during use. Liver toxicity is one of the most vigilant adverse reactions of this drug. Clinical observations show that patients receiving treatment may experience elevated transaminases, and in severe cases, drug-induced liver injury and liver failure may occur. All patients must undergo a comprehensive liver function assessment before starting treatment, including tests for ALT, AST, alkaline phosphatase, and bilirubin. During the treatment period, a strict liver function monitoring program needs to be established. In the early stage, the liver function will be checked once a month. In the later stage, the monitoring frequency will be adjusted according to the situation. Once significant abnormalities in liver function indicators or symptoms of liver injury appear, treatment should be discontinued immediately and corresponding measures should be taken. It is particularly important to note that this drug is absolutely contraindicated in patients with severe hepatic insufficiency (Child-Pugh C grade). Patients with moderate hepatic insufficiency (Child-Pugh B grade) also need to carefully evaluate the risk-benefit ratio before considering its use.

Allergic reactions are another issue that requires serious attention. Severe hypersensitivity reactions, including anaphylactic shock, have been reported with drugs containing similar ingredients, based on postmarketing surveillance data. If patients develop allergic symptoms such as rash, urticaria, difficulty breathing, chest tightness, etc. during medication, they should stop taking the medication immediately and seek medical help. For patients who have experienced adverse reactions in the past when taking drugs containing elexacaftor, tezacaftor or ivacaftor before considering using < /span>Vanzacato/Tizacaftor/Deuterated ivacaftor composite tabletsThe nature and severity of past reactions must be fully evaluated before treatment, and the benefits and risks of treatment must be weighed. If you decide to use it, a more rigorous monitoring plan will need to be developed to detect and deal with possible adverse reactions in a timely manner.

Drug interaction is an important aspect that cannot be ignored in clinical use. Vanzacato/Tizacaftor/The interaction between deuterated ivacaftor composite tablets and the CYP3A system is particularly significant. On the one hand, strong and moderate CYP3A inducers such as carbamazepine and rifampin will significantly reduce drug concentration and affect the therapeutic effect, so combined use should be avoided. On the other hand, CYP3A inhibitors such as ketoconazole and clarithromycin will increase drug exposure and may aggravate adverse reactions. At this time, it is necessary to consider adjusting the dose of vanzacato/tizakato/deuterated ivacaftor composite tablets. This complex drug-drug interaction profile requires physicians to have a detailed understanding of all medications a patient is taking before prescribing, including prescription drugs, over-the-counter drugs, and herbal preparations.

For children and adolescent patients under 18 years of age, special attention needs to be paid to the risk of cataracts. Clinical observations indicate that young cystic fibrosis patients treated with drugs containing ivacaftor may develop non-congenital lens opacities. Therefore, it is recommended that all minor patients receiving vanzacato/tizaccato/deuterated ivacaftor composite tablets should have a baseline eye examination before treatment and regular follow-up during treatment to detect possible lens changes early. This special ocular monitoring requirement makes medication management in pediatric patients more complex and requires the professional involvement of an ophthalmologist.

Taken together, vanzacato/tizakato/Deuterated ivacaftor compound tabletsAlthough it provides a new treatment option for patients with cystic fibrosis, precautions during its use involve multiple systems, requiring both doctors and patients to remain highly vigilant. Standardized pre-medication assessment, strict monitoring during treatment and timely treatment of adverse reactions are key links to ensure safe and effective treatment. Patients should closely cooperate with the doctor's follow-up plan during the medication period and report any abnormal symptoms in a timely manner, so as to maximize the therapeutic value of the medication while controlling potential risks to a minimum.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf